<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250511065690N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-12</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Acupuncture in lumbar spinal canal stenosis ; Effects of Mesotherapy with calcitonin in lumbar spinal canal stenosis</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating effects of Acupuncture versus Mesotherapy with Calcitonin in Patients with Lumbar Spinal Canal stenosis( randomized controlled clinical trial)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83518</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the random allocation method will be 6-block randomization, as follows:

Group A represents individuals receiving the intervention of mesotherapy with calcitonin and therapeutic exercise.

Group B represents individuals receiving acupuncture and therapeutic exercise.

Group C represents individuals receiving therapeutic exercise only.

Next, using a random number table and assigning numbers from 0 to 9 to each possible permutation, a randomized list of 60 participants will be generated. This list will include 10 blocks of 6 participants each (6*10 = 60 total participants), and the allocation of each method to each participant will be determined.

Each participant's group allocation will be assigned through the sealed envelope method, and the analyst will be blinded to the group assignments to prevent bias in the analysis, Blinding description: To ensure concealment, the random sequence method is placed in sealed envelopes in the possession of another person who is unaware of the research process, and the questionnaires are completed by an individual unaware of the group assignment.
Clinical caregiver: We train the person who is responsible for the care and follow-up of patients on how to complete the questionnaire. This person has no knowledge of the type of intervention the patient received. Outcome assessor: The completed questionnaires are given to a person who is unaware of the interventions performed and is asked to determine the degree of pain reduction and increase in function and weight-bearing ability and balance in each individual, according to the questionnaire.</study_design>
      <phase>3</phase>
      <hc_freetext>LUMBAR SPINAL CANAL STENOSIS.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A)mesotherapy with calcitonine and exercises   in the form of three injection sessions (two 50-unit ampoules of calcitonin + 4 cc of 2% lidocaine per session) with an interval of one week. Using sterile disposable 10cc syringes with a 12mm*0.27mm needle and one cc injection at each point. Calcitonin and lidocaine manufacturer: Caspian Tamin. Intervention 2: Intervention group: B)acupuncture and exercise   For acupuncture, 25 x 25 needles are inserted bilaterally at BL-23, BL-25, BL-26, BL-37, BL-40, BL-54, BL-57, LI-4, BL-60, DU-3, DU-4 to a depth of 2.5 cm in the muscles, and DU-20 is inserted intradermally and remains in the patient's body for 30 minutes / Acupuncture needle manufacturer: Huanqiu. Intervention 3: Control group: (c) Exercise therapy . Therapeutic exercises include isometric gluteal muscle exercises, hamstring and calf muscle stretching, and knee bending to the chest. The duration of each exercise is 15 to 30 seconds and is repeated 30 time per day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is NO information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nazanin Rashidirezvan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>no19, ghasrodasht street, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7133844311</zip>
        <telephone>009871</telephone>
        <email>Nazaninrashidi4872@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nazanin Rashidirezvan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>no19, ghasrodasht street, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7133844311</zip>
        <telephone>009871</telephone>
        <email>Nazaninrashidi4872@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 40-75 years old
confirmation of the diagnosis of lumbar spinal canal stenosis by radiography, MRI, or Electrodiagnosis study.
ATleast 6 months should have passed since the onset of symptoms of lumbar spinal canal stenosis ( such as low back pain, claudication, radicular leg pain, etc.)</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnancy
breastfeeding
critical systemic or local infection
uncontrolled diabetes
Rheumatic and collagen vascular diseases
cancer
history of severe hepatic, renal, cardiac, or pulmonary disease
bleeding disorders
use of anticoagulants
Brucellosis
history of spinal canal surgery
Diabetic neuropathy
Concurrent radiculopathy
BMI over 42
history of allergic reaction to the drug used in the study
presence of cauda equina syndrome symptoms(perineal numbness, urinary and fecal incontinence)
muscle weakness with manual muscle test score less than 4 out of 5
inability to communicate and complete the questionnaire
history of acupuncture or calcitonin injection in thepast three months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M48.06</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Spinal stenosis, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A)mesotherapy with calcitonine and exercises   in the form of three injection sessions (two 50-unit ampoules of calcitonin + 4 cc of 2% lidocaine per session) with an interval of one week. Using sterile disposable 10cc syringes with a 12mm*0.27mm needle and one cc injection at each point. Calcitonin and lidocaine manufacturer: Caspian Tamin</i_keyword>
      <i_keyword>Intervention group: B)acupuncture and exercise   For acupuncture, 25 x 25 needles are inserted bilaterally at BL-23, BL-25, BL-26, BL-37, BL-40, BL-54, BL-57, LI-4, BL-60, DU-3, DU-4 to a depth of 2.5 cm in the muscles, and DU-20 is inserted intradermally and remains in the patient's body for 30 minutes / Acupuncture needle manufacturer: Huanqiu</i_keyword>
      <i_keyword>Control group: (c) Exercise therapy . Therapeutic exercises include isometric gluteal muscle exercises, hamstring and calf muscle stretching, and knee bending to the chest. The duration of each exercise is 15 to 30 seconds and is repeated 30 time per day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain Intensity. Timepoint: Before treatment, 4 and 8 weeks after start treatment. Method of measurement: VAS(Visual)analoge scale.</prim_outcome>
      <prim_outcome>Function. Timepoint: Before treatment, 4 and 8 weeks after start treatment. Method of measurement: health Shortform_(survey(SF_36                                                                      Quebec scale(QBPDS disability pain(back.</prim_outcome>
      <prim_outcome>Ability to hop on one leg for 5 steps. Timepoint: Before treatment, 4 and 8 weeks after start treatment. Method of measurement: hopping standard scale (SHS ).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-22</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Shiraz Medical School, Imam Hossein Square, Zand Street, Shiraz Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
